Anticholinergic antiemetics

Introduction

Antiemetics are a broad category of medications used to prevent or relieve nausea and vomiting, symptoms that can occur due to various causes such as motion sickness, postoperative states, pregnancy, chemotherapy, and vestibular disorders. Among the diverse classes of antiemetics, anticholinergic agents represent a unique subset. These drugs act by antagonizing the effects of acetylcholine on muscarinic receptors within the central and peripheral nervous systems, thereby interrupting the emetic reflex pathways.

Anticholinergic antiemetics are particularly effective in managing motion sickness, vestibular disturbances, and to a lesser extent, certain postoperative or drug-induced nausea and vomiting. Their therapeutic application is narrower compared to 5-HT3 receptor antagonists, dopamine antagonists, or neurokinin-1 antagonists, yet they remain important in specific clinical scenarios where vestibular function plays a central role.

---

Pharmacological Basis of Anticholinergic Antiemetics

Role of the Vestibular System and the Emetic Reflex

Nausea and vomiting are controlled by a complex neuroanatomical network involving the vomiting center (VC) in the medulla and the chemoreceptor trigger zone (CTZ) in the area postrema. The vestibular system, particularly the labyrinthine apparatus of the inner ear, plays a crucial role in motion-related nausea. Sensory mismatch, such as discordance between visual and vestibular signals, activates cholinergic and histaminergic pathways that ultimately stimulate the vomiting center.

Mechanism of Action

Anticholinergic antiemetics exert their effect by blocking muscarinic acetylcholine receptors (M1 subtype) located in the vestibular nuclei and the vomiting center. By dampening cholinergic transmission in these areas, they reduce the excitatory signals that trigger nausea and vomiting.

This mechanism makes them particularly effective in motion sickness, labyrinthitis, and other vestibular-origin nausea states, but less so for nausea caused by toxins, metabolic disturbances, or chemotherapy, where serotonin or dopamine pathways dominate.

---

Common Anticholinergic Antiemetic Agents

The most clinically relevant and widely used drug in this class is scopolamine (also known as hyoscine). Other drugs, such as dimenhydrinate and meclizine, while traditionally classified as antihistamines, also exhibit significant anticholinergic properties and are sometimes grouped functionally with anticholinergic antiemetics. However, scopolamine remains the prototype and most specific agent in this category.

---

Scopolamine (Hyoscine)

General Overview

Scopolamine is a tertiary amine alkaloid derived from plants of the Solanaceae family. Its ability to cross the blood-brain barrier efficiently makes it particularly potent in central cholinergic blockade. It is most commonly used in the form of transdermal patches for the prevention of motion sickness and postoperative nausea.

Mechanism of Action

Scopolamine is a competitive antagonist at muscarinic acetylcholine receptors (primarily M1) in the central nervous system. By inhibiting cholinergic transmission in the vestibular nuclei and vomiting center, it prevents the neurogenic activation of nausea and vomiting pathways.

Clinical Uses

1. Motion sickness – one of the most effective agents for prevention, especially for prolonged travel by sea, air, or land.

2. Postoperative nausea and vomiting (PONV) – used as prophylaxis, particularly in high-risk patients.

3. Vestibular disorders – including labyrinthitis and Ménière’s disease, though usage here has declined with modern therapies.

Dosage and Administration

• Transdermal Patch:

  • Each patch delivers 1.5 mg of scopolamine over 72 hours (0.5 mg/day).

  • Applied behind the ear at least 4 hours before travel or surgery.

  • Patches may be replaced every 3 days if needed.

• Oral/Parenteral forms (less common due to side effects):

  • Oral: 0.3–0.6 mg every 6–8 hours.

  • Subcutaneous/IM: 0.2–0.6 mg every 4–6 hours.

---

Other Agents with Anticholinergic Properties

While scopolamine is the only agent classified strictly as an anticholinergic antiemetic, several other drugs with mixed antihistaminic and anticholinergic activity are often employed for similar indications:

1. Dimenhydrinate (Dramamine)

   • Primarily an H1 receptor antagonist, but also exhibits central anticholinergic effects.

   • Effective for motion sickness and vestibular nausea.

   • Dose: 50–100 mg orally every 4–6 hours (maximum 400 mg/day).

2. Meclizine

   • An antihistamine with strong anticholinergic activity.

   • Used for motion sickness and vertigo.

   • Dose: 25–50 mg orally 1 hour before travel, repeat every 24 hours as needed.

3. Cyclizine

   • Similar to meclizine, with both antihistamine and anticholinergic effects.

   • Used for motion sickness and nausea due to vestibular disturbances.

   • Dose: 50 mg orally every 4–6 hours (maximum 200 mg/day).

---

Adverse Effects

The side effect profile of anticholinergic antiemetics stems directly from muscarinic receptor blockade, affecting multiple organ systems:

Central Nervous System

• Drowsiness and sedation

• Dizziness

• Confusion, especially in elderly patients

• Memory impairment

• Hallucinations (rare, high doses or sensitive populations)

Peripheral Effects

• Dry mouth (xerostomia)

• Blurred vision due to cycloplegia and mydriasis

• Urinary retention (problematic in benign prostatic hyperplasia)

• Constipation from reduced gastrointestinal motility

• Tachycardia due to vagal inhibition

Severe Reactions

• Delirium and toxic psychosis in overdose

• Angle-closure glaucoma precipitation

• Severe urinary obstruction in predisposed patients

---

Contraindications

Anticholinergic antiemetics should be avoided or used with caution in:

1. Glaucoma (especially narrow-angle glaucoma, due to risk of increased intraocular pressure).

2. Urinary tract obstruction (e.g., benign prostatic hyperplasia).

3. Myasthenia gravis (worsening of muscular weakness).

4. Elderly patients (increased risk of confusion and hallucinations).

5. Children under 12 years (increased susceptibility to central anticholinergic toxicity).

---

Precautions

1. Pregnancy and Lactation

   • Limited data on safety; scopolamine should be used only when necessary.

   • May reduce milk production in breastfeeding women due to anticholinergic action.

2. Driving and Machinery Use

   • Sedative and visual side effects impair psychomotor performance.

3. Drug Abuse Potential

   • Rare, but some reports of scopolamine misuse due to hallucinogenic effects at high doses.

---

Drug Interactions

Anticholinergic antiemetics may interact with other medications, potentiating side effects or altering efficacy:

• CNS depressants (alcohol, benzodiazepines, opioids, antihistamines): Additive sedation and drowsiness.

• Other anticholinergics (tricyclic antidepressants, antipsychotics, antiparkinsonian drugs): Increased risk of anticholinergic toxicity (urinary retention, constipation, delirium).

• Antihypertensive agents: May blunt compensatory reflex tachycardia.

• Topical antiglaucoma medications: Reduced effectiveness due to mydriatic effects of scopolamine.

---

Clinical Efficacy and Limitations

Anticholinergic antiemetics are highly effective for motion sickness prophylaxis, but their role in broader antiemetic therapy is limited. Unlike serotonin antagonists (ondansetron, granisetron) or dopamine antagonists (metoclopramide, prochlorperazine), they do not address chemotherapy-induced nausea and vomiting or severe postoperative vomiting reliably.

Their main advantages are:

• Long duration of effect (transdermal scopolamine patch lasting 72 hours).

• Convenience of administration for travel-related nausea.

• Targeted efficacy for vestibular-mediated symptoms.

Their main disadvantages are:

• Prominent side effect profile (anticholinergic burden).

• Limited spectrum of antiemetic efficacy.

• Unsuitability in elderly and patients with comorbidities like glaucoma or urinary obstruction.